Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.
Br J Cancer
; 117(10): 1450-1458, 2017 Nov 07.
Article
de En
| MEDLINE
| ID: mdl-28972961
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Tumeurs colorectales
/
Marqueurs biologiques tumoraux
/
Résistance aux médicaments antinéoplasiques
/
Protéines proto-oncogènes B-raf
/
Mutation
/
Antinéoplasiques
Type d'étude:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limites:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Langue:
En
Journal:
Br J Cancer
Année:
2017
Type de document:
Article
Pays d'affiliation:
Japon
Pays de publication:
Royaume-Uni